
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1694776/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?. Autoimmunity Reviews, 2020, 19, 102524.	5.8	231
2	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,) Tj ETQq0 0 0	rgBT_/Qverl	ock 10 Tf 50 7
3	Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment. Current Medicinal Chemistry, 2013, 20, 3370-3396.	2.4	71
4	Polyunsaturated fatty acids: any role in rheumatoid arthritis?. Lipids in Health and Disease, 2017, 16, 197.	3.0	56
5	Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. Autoimmunity Reviews, 2011, 10, 631-635.	5.8	50
6	Physical activity and sedentary behavior in patients with Systemic Lupus Erythematosus. PLoS ONE, 2018, 13, e0193728.	2.5	48
7	Leptin in immuno-rheumatological diseases. Cellular and Molecular Immunology, 2011, 8, 203-212.	10.5	45
8	The Association of Olfactory Dysfunction, Frailty, and Mortality Is Mediated by Inflammation: Results from the InCHIANTI Study. Journal of Immunology Research, 2019, 2019, 1-8.	2.2	42
9	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Arthritis Research and Therapy, 2019, 21, 204.	3.5	40
10	One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opinion on Biological Therapy, 2020, 20, 813-821.	3.1	40
11	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmunity Reviews, 2021, 20, 102738.	5.8	38
12	Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. Autoimmunity Reviews, 2021, 20, 102750.	5.8	36
13	Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. Lupus, 2017, 26, 1463-1472.	1.6	35
14	Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. Rheumatology International, 2020, 40, 951-958.	3.0	34
15	Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. PLoS ONE, 2018, 13, e0205506.	2.5	28
16	Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results. Journal of Immunology Research, 2018, 2018, 1-6.	2.2	27
17	Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e) Tj ETQq1 1 0.74	8431 <b>2</b> 42gBT	/Overlock 10
18	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. Arthritis Research and Therapy, 2021, 23, 213.	3.5	25

2

#	Article	IF	CITATIONS
19	Relationship between leptin and regulatory T cells in systemic lupus erythematosus: preliminary results. European Review for Medical and Pharmacological Sciences, 2016, 20, 636-41.	0.7	24
20	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clinical Rheumatology, 2017, 36, 251-260.	2.2	22
21	Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "sine psoriasis― Clinical Rheumatology, 2019, 38, 2547-2552.	2.2	21
22	Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment. Rheumatology and Therapy, 2020, 7, 867-882.	2.3	21
23	Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. Expert Review of Clinical Immunology, 2020, 16, 409-420.	3.0	21
24	The association between duration of remission, fatigue, depression and health-related quality of life in Italian patients with systemic lupus erythematosus. Lupus, 2019, 28, 1705-1711.	1.6	20
25	Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism. International Journal of Biochemistry and Cell Biology, 2018, 99, 161-168.	2.8	19
26	Enteropathic spondyloarthritis: Results from a large nationwide database analysis. Autoimmunity Reviews, 2020, 19, 102457.	5.8	18
27	Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy. Microvascular Research, 2017, 114, 41-45.	2.5	17
28	Homocysteinylated alpha 1 antitrypsin as an antigenic target of autoantibodies in seronegative rheumatoid arthritis patients. Journal of Autoimmunity, 2020, 113, 102470.	6.5	17
29	Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. Clinical Rheumatology, 2020, 39, 2663-2670.	2.2	17
30	Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. Anticancer Research, 2020, 40, 983-990.	1.1	17
31	The IL33/ST2 axis in Sjogren syndrome in relation to disease activity. European Review for Medical and Pharmacological Sciences, 2016, 20, 1295-9.	0.7	17
32	The relation between, metabolic syndrome and quality of life in patients with Systemic Lupus Erythematosus. PLoS ONE, 2017, 12, e0187645.	2.5	16
33	Leptin in autoimmune mechanisms of systemic rheumatic diseases. Cancer Letters, 2018, 423, 139-146.	7.2	16
34	A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis. Rheumatology, 2020, 59, 1767-1769.	1.9	16
35	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. Rheumatology, 2022, 61, 4124-4129.	1.9	16
36	Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management. Drugs and Aging, 2019, 36, 909-925.	2.7	15

#	Article	IF	CITATIONS
37	Pathogenesis of Psoriatic Arthritis. Critical Reviews in Immunology, 2019, 39, 361-377.	0.5	15
38	Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease. Rheumatology, 2022, 62, 321-329.	1.9	15
39	Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis. Clinical Rheumatology, 2021, 40, 4253-4258.	2.2	12
40	Phase angle could be a marker of microvascular damage in systemic sclerosis. Nutrition, 2020, 73, 110730.	2.4	11
41	Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis. Clinical Rheumatology, 2019, 38, 971-976.	2.2	10
42	Secukinumabâ€induced subacute cutaneous lupus erythematosus. Dermatologic Therapy, 2020, 33, e13417.	1.7	10
43	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. Scientific Reports, 2021, 11, 12455.	3.3	10
44	New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report. Scandinavian Journal of Rheumatology, 2020, 49, 75-76.	1.1	9
45	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. Frontiers in Medicine, 2022, 9, 878797.	2.6	9
46	Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. Expert Opinion on Pharmacotherapy, 2020, 21, 785-796.	1.8	8
47	A longitudinal study on caring behaviors of Italian nursing students. Nurse Education Today, 2020, 88, 104377.	3.3	8
48	Pattern of sleep dysfunction in systemic lupus erythematosus: a cluster analysis. Clinical Rheumatology, 2019, 38, 1561-1570.	2.2	7
49	Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin. Journal of Scleroderma and Related Disorders, 2019, 4, 71-76.	1.7	7
50	Clinical features of patients with systemic lupus erythematosus according to health-related quality of life, entity of pain, fatigue and depression: a cluster analysis. Clinical and Experimental Rheumatology, 2019, 37, 535-539.	0.8	7
51	Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. Scientific Reports, 2022, 12, 7498.	3.3	7
52	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6. Pharmaceuticals, 2022, 15, 622.	3.8	7
53	Association Between Minor Salivary Gland Biopsy During Sjӧgren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 686457.	4.8	6
54	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. Clinical Rheumatology, 2022, 41, 641-647.	2.2	6

#	Article	IF	CITATIONS
55	In systemic sclerosis, microvascular and hands digital arteries damage correlates with serum levels of endostatin. Microcirculation, 2018, 25, e12449.	1.8	5
56	Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study. Cardiology Research and Practice, 2019, 2019, 1-7.	1.1	5
57	Demographic and clinical differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis: results from a multicentre retrospective study in the Lazio region of Italy. Clinical and Experimental Rheumatology, 2020, 38, 88-93.	0.8	5
58	Adult-onset Still's disease with elderly onset, results from a multicentre study. Clinical and Experimental Rheumatology, 2022, , .	0.8	5
59	Systemic Lupus Erythematosus Patients with and without Neuropsychiatric Manifestations: A Neck and Transcranial Duplex Sonography Study. International Journal of Immunopathology and Pharmacology, 2012, 25, 1157-1165.	2.1	4
60	Serum level of endostatin and digital ulcers in systemic sclerosis patients. International Wound Journal, 2018, 15, 424-428.	2.9	4
61	Moderateâ€toâ€severe plaque psoriasis, described by PASI ≥10%, can be associated with higher cardiovascular risk according to seven risk algorithms: Results of a 10â€year singleâ€center retrospective study and clinical management of psoriatic patients with cardiovascular risk. Dermatologic Therapy, 2020, 33. e14451.	1.7	4
62	Erythema Multiforme Induced by Secukinumab. Journal of Clinical Rheumatology, 2021, 27, e177-e178.	0.9	4
63	Erectile dysfunction: Imbalance between pro-angiogenic and anti-angiogenic factors in systemic sclerosis. European Journal of Internal Medicine, 2018, 53, e17-e18.	2.2	3
64	Matters of the Heart: The Case of TNFÂ-Targeting Drugs. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 79-87.	3.4	3
65	Parasympathetic activity increases with digital microvascular damage and vascular endothelial growth factor in systemic sclerosis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 24-27.	0.8	3
66	Inflammation as a mediator of the association between osteoporosis and hearing loss in older subjects: a population-based study. European Review for Medical and Pharmacological Sciences, 2018, 22, 1451-1456.	0.7	3
67	Utility of ultrasound in the diagnosis of chronic worsened gout. Journal of Medical Ultrasonics (2001), 2013, 40, 467-469.	1.3	2
68	Intrarenal arterial stiffness is increased in systemic sclerosis patients with anti–ribonucleic acid polymerase III antibodies. Rheumatology, 2017, 56, 1039-1041.	1.9	2
69	Beauty is not perfection: what Leonardo's Lady with an Ermine can suggest to aesthetic surgery. European Journal of Plastic Surgery, 2021, 44, 161-162.	0.6	2
70	JAK inhibitors in immune-mediated rheumatic diseases: From a molecular perspective to clinical studies. Journal of Molecular Graphics and Modelling, 2021, 104, 107789.	2.4	2
71	Serum resistin is predictive marker of development of new digital ulcers in systemic sclerosis. Clinical and Experimental Medicine, 2021, , 1.	3.6	2
72	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. Clinical and Experimental Rheumatology, 2021, 39, 995-1002.	0.8	2

LUCA NAVARINI

#	Article	IF	CITATIONS
73	Metabolic syndrome is associated with better quality of sleep in the oldest old: results from the "Mugello Study― Diabetology and Metabolic Syndrome, 2020, 12, 46.	2.7	1
74	Long-term safety of rituximab in primary SjĶgren's syndrome: the experience of a single centre. Journal of Rheumatology, 2021, , jrheum.210441.	2.0	1
75	Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future. Journal of Experimental Pharmacology, 2020, 12, 487-502.	3.2	1
76	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
77	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard. Clinical and Experimental Rheumatology, 0, , .	0.8	0
78	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 0, , .	0.8	0
79	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard Clinical and Experimental Rheumatology, 2022, , .	0.8	0
80	2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus. Biomedicines, 2022, 10, 1675.	3.2	0